Genetically determined apo B levels and peak LDL density predict angiographic response to intensive lipid-lowering therapy
- 1 April 2006
- journal article
- research article
- Published by Wiley in Journal of Internal Medicine
- Vol. 259 (4) , 401-409
Abstract
Lipid-lowering therapy (LL-Rx) reduces coronary artery disease (CAD) but the response varies amongst individuals. We investigated the contribution of three genetic forms of dyslipidaemia characterized by elevated plasma apo B, familial hypercholesterolaemia (FH), familial combined hyperlipidaemia (FCHL), and elevated Lp(a), to the angiographic response with LL-Rx. Fifty-one men, with premature CAD and elevated plasma apo B, were selected in whom a genetic diagnosis was based on lipid phenotypes in relatives. Subjects received conventional (diet +/- colestipol) or intensive LL-Rx (niacin or lovastatin plus colestipol). Clinical parameters and CAD severity were measured before and after 2 years of treatment. Twenty-seven patients had FCHL, 12 FH and 12 elevated Lp(a). Regression of coronary stenosis was dependent on the effect of therapy (P < 0.001), genetic form of dyslipidaemia (P = 0.004) and the interaction between the two variables (P = 0.02). Significant regression of coronary stenosis occurred only in FCHL and Lp(a) (P = 0.03, vs. control groups); CAD progression was only slowed in FH. Three genetic forms of dyslipidaemia were associated with different angiographic outcomes during intensive LL-Rx. Different forms of dyslipidaemia therefore may require different lipid-lowering strategy. Patients with FH and buoyant LDL require more aggressive reduction of LDL cholesterol whilst those with either FCHL or elevated Lp(a) with dense LDL need LDL cholesterol reduction as well as therapies aimed at reduction of the small, dense LDL particles.Keywords
This publication has 25 references indexed in Scilit:
- Low-Density Lipoprotein Subfractions and the Long-Term Risk of Ischemic Heart Disease in MenArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Small, Dense LDL and Elevated Apolipoprotein B Are the Common Characteristics for the Three Major Lipid Phenotypes of Familial Combined HyperlipidemiaArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- Effect of Weight Loss with Reduction of Intra-Abdominal Fat on Lipid Metabolism in Older MenThe Journal of Clinical Endocrinology & Metabolism, 2000
- A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarctionJAMA, 1996
- Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a)1995
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995
- LDL Physical and Chemical Properties in Familial Combined HyperlipidemiaArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Effect of hepatic lipase on LDL in normal men and those with coronary artery disease.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993
- Low-density lipoprotein subclass patterns and risk of myocardial infarctionJAMA, 1988
- Evidence for the role of hepatic endothelial lipase in the metabolism of plasma high density lipoprotein2 in manAtherosclerosis, 1980